Given the importance of IL-1β and IL-18 in AAA pathogenesis, we examined whether attenuation of experimental AAAs by gasdermin D inhibitor disulfiram is associated with reduced systemic levels of IL-1β and IL-18. This evidence concerns the gene GSDMD and achalasia-alacrima syndrome.